Delcath Systems Inc

DCTH remains in a Stage 2 advancing phase with long- and medium-term uptrends intact. However, price is extended and marked as extremely overbought, consolidating above the rising EMAs without a clear upside trigger. Execution is deferred until a pullback into the 9/21 EMA support zone resolves, offering a lower-risk entry aligned with the advancing structure.

• ↑Shares rose ~52% Q/Q and ~51% Y/Y, outpacing the S&P 500
• ↑Earnings estimates revised from -$0.88 to -$0.17, indicating improvement
• ↓Earnings yield -1.99 and weak profitability indicate losses